[A prospective multicenter study of rituximab combined with high-dose chemotherapy and autologous peripheral blood stem cell transplantation for aggressive B-cell lymphoma].

Abstract

OBJECTIVE:

To investigate the feasibility and efficacy of rituximab combined with high-dose chemotherapy supported by autologous peripheral blood stem cell transplantation (ASCT) in patients with aggressive B-cell non-Hodgkin lymphoma (NHL).

METHODS:

Twenty-eight patients with aggressive B-cell NHL (22 newly diagnosed, 6 relapsed) were enrolled in this study. The high-dose chemotherapy included CHOP regimen (CTX + ADM + VCR + PDN) for the newly diagnosed patients and DICE (DEX + IFO + DDP + VP-16) or EPOCH (VP-16 + PDN + VCR + CTX + ADM) for the relapsed patients. Each patient received infusion of rituximab at a dose of 375 mg/m(2) for four times, on D1 before and on D7 of peripheral blood stem cell mobilization, and on D1 before and D8 after stem cell reinfusion.

RESULTS:

Complete remission was achieved in all patients after high dose chemotherapy and ASCT. At a median follow-up of 37 months, the estimated overall 4-year survival and progression-free survival rate for all patients were 75.0% and 70.3%, respectively, while both were 72.7% for the previously untreated patients. The therapy was generally well tolerated with few side-effects attributable to rituximab.

CONCLUSION:

These results suggest that adding rituximab to high-dose chemotherapy with peripheral blood stem cell transplantation is feasible and may be beneficial for patients with aggressive B-cell non-Hodgkin lymphoma.

• Authors: Yuan-kai Shi, Sheng Yang, Xiao-hong Han, Jun Ma, Han-yun Ren, Xi-nan Cen, Shu-yun Zhou, Chun Wang, Wen-qi Jiang, Hui-qiang Huang, Jian-ming Wang, Jun Zhu, Hu Chen, Ming-zhe Han, He Huang, Xiao-mei Shen, Peng Liu, Xiao-hui He
• Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology] (Zhonghua Zhong Liu Za Zhi) Vol. 31 Issue 8 Pg. 592-6 (Aug 2009) ISSN: 0253-3766 [Print] China
• PMID: 20021946 (Publication Type: Clinical Trial, English Abstract, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal, Murine-Derived
• Antineoplastic Agents
• Rituximab
• Vincristine
• Etoposide
• Dexamethasone
• Doxorubicin
• Cyclophosphamide
• Prednisolone
• Cisplatin
• Ifosfamide
• Prednisone

Topics

• Adolescent
• Adult
• Antibodies, Monoclonal, Murine-Derived (adverse effects, therapeutic use)
• Antineoplastic Agents (adverse effects, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Cisplatin (adverse effects, therapeutic use)
• Combined Modality Therapy
• Cyclophosphamide (adverse effects, therapeutic use)
• Dexamethasone (adverse effects, therapeutic use)
• Disease-Free Survival
• Doxorubicin (adverse effects, therapeutic use)
• Etoposide (adverse effects, therapeutic use)
• Female
• Fever (chemically induced, etiology)
• Humans
• Ifosfamide (adverse effects, therapeutic use)
• Lymphoma, Large B-Cell, Diffuse (therapy)
• Male
• Middle Aged
• Peripheral Blood Stem Cell Transplantation
• Prednisolone (adverse effects, therapeutic use)
• Prednisone (adverse effects, therapeutic use)
• Prospective Studies
• Remission Induction
• Rituximab
• Survival Rate
• Vincristine (adverse effects, therapeutic use)
• Vomiting (chemically induced)
• Young Adult